Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Exploratory Analysis Shows Perioperative Nivolumab Confers Benefit in Resectable NSCLC, Irrespective of Neoadjuvant Treatment Cycles

March 20th 2024

Perioperative nivolumab improved responses in resectable non–small cell lung cancer, irrespective of the number of neoadjuvant treatment cycles completed.

SBRT Shines in Early-Stage NSCLC and Demonstrates Efficacy With Immunotherapy

March 16th 2024

Stereotactic ablative radiotherapy has shown clinical benefit in combination with immunotherapy in early-stage NSCLC, making it a viable treatment to consider.

Advanced Radiation Techniques Could Aid in Cardiac Sparing in Lung, Breast, and Esophageal Cancer Treatment

March 15th 2024

Charles B. Simone II, MD, FASTRO, FACRO, discusses advanced radiation techniques that could reduce cardiac toxicities.

Dr Zaha on the Risk of Cardiovascular Toxicity in Patients With Lung Cancer

March 15th 2024

Vlad Gabriel Zaha, MD, PhD, discusses the risk of cardiovascular toxicity in patients with lung cancer undergoing treatment with radiation.

Dr Singh on the Utility of Radiation Therapy in Lung Cancer

March 14th 2024

Raj Singh, MD, discusses radiation therapy in patients with metastatic lung cancer, highlighting the evolution of treatment within this landscape.

Brown Details the Evolving Role of PCI and HA-PCI in Small Cell Lung Cancer

March 14th 2024

Paul D. Brown, MD, gives a history of prophylactic cranial irradiation in small cell lung cancer and describes its standing in the treatment paradigm.

Study Reveals New Insights Into Immune System Role in Lung Cancer Risk

March 14th 2024

A study sheds light on how immune genetics influence lung cancer risk, potentially paving the way for enhanced prevention strategies and screening.

Dr Pellini on the Clinical Utility of ctDNA Assays in NSCLC

March 13th 2024

Bruna Pellini, MD, discusses the utility of circulating tumor DNA assays in non–small cell lung cancer.

Perioperative Tislelizumab Shows Marked Benefit in Both Squamous and Nonsquamous Resectable NSCLC

March 13th 2024

Federico Cappuzzo, MD, discusses the clinical significance of the RATIONALE-315 trial of perioperative tislelizumab in non–small cell lung cancer.

FDA Accepts NDA for Ensartinib in Metastatic ALK+ NSCLC

March 13th 2024

The FDA has accepted a new drug application for ensartinib in metastatic ALK-positive non–small cell lung cancer.

TNO155 Plus Spartalizumab or Ribociclib Elicits Disease Control, Is Safe in Advanced Solid Tumors

March 12th 2024

TNO155 plus spartalizumab or ribociclib was well tolerated and demonstrated disease control in patients with advanced solid tumors.

Dr Levy on the Potential for ADCs in NSCLC

March 12th 2024

Benjamin Levy, MD, explores the potential role of antibody-drug conjugates in non–small cell lung cancer.

Neoadjuvant Immunotherapy is Helping Redefine Resectability in NSCLC

March 11th 2024

Neel P. Chudgar, MD, discusses the nuances of defining resectability in patients with non–small cell lung cancer.

ABSK061 Demonstrates Safety, Preliminary Efficacy in FGFR2/3+ Advanced Solid Tumors

March 7th 2024

ABSK061 was well tolerated and elicited responses in patients with advanced solid tumors harboring FGFR2/3 alterations.

Taletrectinib Under NMPA Review in China for First-Line ROS1+ NSCLC

March 5th 2024

China’s National Medical Products Administration has accepted the second NDA for first-line taletrectinib for ROS1-positive non–small cell lung cancer.

Levy Delves Into the Evolution of ADCs in NSCLC

March 4th 2024

Benjamin Philip Levy, MD, discusses lingering questions regarding the use of antibody-drug conjugates in lung cancer.

FDA Lifts Clinical Hold on Trial Investigating LN-145 in NSCLC

March 4th 2024

The partial clinical hold placed on the phase 2 IOV-LUN-202 trial of LN-145 in non–small cell lung cancer has been lifted by the FDA.

EMA Validates MAAs for Datopotamab Deruxtecan in NSCLC and HR+ Breast Cancer

March 4th 2024

MAAs for datopotamab deruxtecan in non–small cell lung cancer and hormone receptor–positive, HER2-negative breast cancer have been validated by the EMA.

Dr Mohindra on Updates in SCLC Management

March 1st 2024

Nisha A. Mohindra, MD, discusses key updates for the management of small cell lung cancer.

FDA Approves Frontline Amivantamab Plus Chemo for EGFR Exon 20 Insertion+ NSCLC

March 1st 2024

The FDA has approved amivantamab plus chemotherapy for the frontline treatment of select patients with EGFR exon 20 insertion+ non–small cell lung cancer.